Publications
Publications
- September 2003 (Revised March 2007)
- HBS Case Collection
Direvo Biotech AG
Abstract
Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes and pharmaceutical products, either through partnerships or its own product development, with very different risk/return structures. The resulting hybrid business model is a constant source of discussion between the Direvo management team and the lead investor, Techno Venture Management. How should Direvo extract value from the spectrum of business options to develop an optimal exit strategy?
Keywords
Business Model; Decisions; Business Exit or Shutdown; Value; Business Startups; Biotechnology Industry; Germany
Citation
Roberts, Michael J., Vincent Dessain, and Anders Sjoman. "Direvo Biotech AG." Harvard Business School Case 804-017, September 2003. (Revised March 2007.)